Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with <scp>PSA</scp> &lt;10 ng/ml and <scp>PI‐RADS</scp> v2.1 = 3 lesions

Can Hu,Jiale Sun,Zhenyu Xu,Zhiyu Zhang,Qi Zhou,Jiangnan Xu,Hao Chen,Chao Wang,Jun Ouyang
DOI: https://doi.org/10.1002/cam4.5100
IF: 4.711
2022-01-01
Cancer Medicine
Abstract:Until now, this is the first nomogram that predicts PCa and csPCa in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions. Furthermore, PI-RADS v2.1 = 3 subgroups were considered to be an independent risk factor in our model. Our nomogram may assist urologists in biopsy decision making for these so-called "double gray zone" patients.
What problem does this paper attempt to address?